Given the recent classification of gliomas based on IDH mutation and the long time course of this disease, the article emphasizes the need for a thoughtful and comprehensive strategy to study patient outcomes and devise methods of cognitive risk reduction. The gene discussed is IDH2; the disease is central nervous system cancer.